Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

por Allouchery, Marion, Lombard, Thomas, Martin, Mickael, Rouby, Franck, Sassier, Marion, Bertin, Celia, Atzenhoffer, Marina, Miremont-Salame, Ghada, Perault-Pochat, Marie-Christine, Puyade, Mathieu
Publicado 2020